Spots Global Cancer Trial Database for Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant

Official Title: Blood Samples to Identify Biomarkers for Post-Transplant Cyclophosphamide

Study ID: NCT04160390

Conditions

Allogeneic Hematopoietic Stem Cell Transplant Recipient

Donor

Malignant Neoplasm

Interventions

Biospecimen Collection-Blood

Biospecimen Collection-Stool

Study Description

Brief Summary: This trial uses blood samples to understand how patients' bodies process and respond to a drug called cyclophosphamide given after a donor stem cell transplant. Identifying biomarkers (molecules that can indicate normal or abnormal processes) may help researchers develop a blood test that can be used to predict how well patients will process and respond to cyclophosphamide.

Detailed Description: "Ancillary-Correlative" study type PRIMARY OBJECTIVES: I. To determine whether endogenous metabolomics compounds obtained before cyclophosphamide administration can predict the ratio of 4hydroxycyclophosphamide to cyclophosphamide area under the curve (4HCY/CY AUC). II. To evaluate mathematic models of CY and mycophenolic acid (MPA) pharmacokinetics and develop mathematic models including these pharmacokinetics, -omics data and clinical outcomes. SECONDARY OBJECTIVES: I. To assess if recipients' metabolomics and pharmacokinetics (e.g., CY and its metabolites AUCs) are associated with acute graft versus host disease (GVHD) and other clinical outcomes. II. To assess the association of the intestinal microbiome with the plasma metabolome, acute GVHD and other clinical outcomes. III. To obtain donor blood samples at one time pre-transplant and assess if donors' metabolomics are associated with acute GVHD and other clinical outcomes. EXPLORATORY OBJECTIVE: I. Donor and recipient germline deoxyribonucleic acid (DNA) isolation and genomic analysis. OUTLINE: Participants are assigned to 1 of 2 arms. ARM I (PATIENTS RECEIVING A HAPLOIDENTICAL TRANSPLANT): Patients undergo collection of blood prior to transplant, on day 0, days 3-7, day 14, and day 21. Patients also undergo collection of saliva prior to transplant and collection of stool prior to and post-transplant. Donors undergo collection of blood and saliva within 8 weeks prior to donation.